. 2017 Sep;23(9):10.18553/jmcp.2017.23.9.980. doi: 10.18553/jmcp.2017.23.9.980

TABLE 2.

Adherence Measures of OAC Cohorts

Treatment Patterns and Adherence	Rivaroxaban Cohort [A] (n = 13,645)	Apixaban Cohort [B] (n = 6,304)	Dabigatran Cohort [C] (n = 3,360)	Warfarin Cohort [D] (n = 13,366)	P Value^a
Treatment Patterns and Adherence	Rivaroxaban Cohort [A] (n = 13,645)	Apixaban Cohort [B] (n = 6,304)	Dabigatran Cohort [C] (n = 3,360)	Warfarin Cohort [D] (n = 13,366)	[A] vs. [B]	[A] vs. [C]	[A] vs. [D]
Treatment duration, days, mean (SD)	452 (183)	402 (156)	485 (196)	496 (196)	–	–	–
Number of dispensing per patient, mean (SD)	11.41 (6.0)	10.50 (5.2)	11.05 (6.2)	11.31 (8.8)	–	–	–
Days supply per dispensing, mean (SD)	44.44 (24.1)	41.68 (21.9)	45.35 (24.4)	59.87 (41.1)	–	–	–
MPR^b
MPR, mean (SD)	0.86 (0.2)	0.85 (0.2)	0.81 (0.2)	0.80 (0.2)	0.001	< 0.001	< 0.001
Adherent patients, % (MPR ≥ 0.80)	78.1	75.7	66.4	59.0	< 0.001	< 0.001	< 0.001
Adherent patients, % (MPR ≥ 0.90)	57.6	53.0	45.5	37.2	< 0.001	< 0.001	< 0.001
Unadjusted adherence at 6 months^c
% of patients with PDC ≥ 0.80	80.1	75.8	69.2	64.5	< 0.001	< 0.001	< 0.001
% of patients with PDC ≥ 0.90	63.5	56.9	51.3	47.1	< 0.001	< 0.001	< 0.001

^aP values were estimated using Student’s t-tests for continuous variables and chi-squared tests for categorical variables.

^bDefined as the number of days supply between the first and the last dispensing over treatment duration. Treatment duration spanned from index date until earliest date between end of data availability, a curative procedure, and end of insurance coverage.

^cUnadusted adherence was calculated as the proportion of patients with PDC ≥ 0.80 or PDC ≥ 0.90.

MPR = medication possession ratio; PDC = proportion of days covered; SD = standard deviation.